GRI Stock Catalyst: GRI Bio Strengthens Clinical Proof-of-Concept for GRI-0621 with Positive Phase 2a Study Data

Jan 7, 2026 · 6:58pm ET

GRI Bio announced additional positive data from a Phase 2a study in Idiopathic Pulmonary Fibrosis.

Max move

+33.3%

High of day $11.03

Sparker timei

6:58pm ET

GRI · Jan 7, 2026

CATALYST DATE · 1-MINUTE BARS

Catalyst Summary

GRI Bio, Inc. (GRI) announced on January 8, 2026, additional positive data from a Phase 2a study evaluating GRI-0621 in patients with Idiopathic Pulmonary Fibrosis (IPF). The study demonstrated strengthened clinical proof-of-concept for GRI-0621 compared to placebo.

The announcement detailed that the Phase 2a study provided further evidence supporting the therapeutic potential of GRI-0621 in treating IPF. The data showed significant improvements in key clinical endpoints, reinforcing the drug's efficacy profile.

GRI Bio has a free float of 2,514,800 shares and 2,515,300 shares outstanding.

This summary was generated by AI from public sources and may contain errors. Not financial advice. Trade at your own risk.

Real-time alerts

Get notified the next time GRI sparks.

Download Sniper App →

Catch the next GRI-style move in real time.

Day Trader Sniper alerts you the moment a setup like this triggers: premarket, open, or intraday.

Watch demo Download Free →